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Ding-Wei Kuang1,2†, Chiu-Leong Li1†, Un-I Kuok1*, Kin Cheung1, Weng-In Lio1 and Jing Xin1,2Abstract
Background: Cardiovascular disease is the leading cause of mortality among peritoneal dialysis (PD) patients in
Macao. Increased arterial stiffness determined by pulse wave velocity (PWV) has been established as an
independent predictor of cardiovascular mortality in end-stage renal disease patients. The present study aims to
investigate the relationship between arterial stiffness and its associated risk factors in chronic PD patients.
Methods: A total of 96 chronic PD patients (48 males/48 females) were included in the cross-sectional study.
Arterial stiffness was assessed by brachial-ankle PWV (baPWV). Patients were divided into two subgroups according
to mean baPWV value. On enrollment, clinical characteristics and biochemical parameters were collected.
Results: Compared with low baPWV group patients, high baPWV group patients were significant older (p<0.001)
and more likely to have a high proportion of female gender (p=0.004) as well as previous CVD history (p=0.008).
Serum albumin, pre-albumin levels and residual renal creatinine clearance (CCr) were significantly lower but the
serum ferritin level was significantly higher in high baPWV group patients than in low baPWV group patients (all
p<0.01). BaPWV was positively associated with age (r=0.534, p<0.001), Charlson comorbidity index (r=0.350, p<0.001)
and serum ferritin level (r=0.340, p=0.001). Meanwhile, baPWV negatively correlated with serum albumin (r=−0.479,
p<0.001), pre-albumin levels (r=−0.320, p=0.003) and residual renal CCr (r=−0.177, p=0.048). Age-adjusted partial
correlation test found a significant correlation between baPWV and CRP (r=0.462, p<0.001). Multivariate regression
analysis showed that baPWV was independently associated with age (p<0.001), serum albumin level (p=0.015),
CRP (p=0.019) and residual renal CCr (p=0.045).
Conclusion: Arterial stiffness, assessed by baPWV, had an independent correlation with age, serum albumin level,
CRP level and residual renal CCr among PD patients in Macao.
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Besides Hong Kong, Macao is the other special admin-
istrative region (SAR) belongs to the People’s Republic
of China. As the only government hospital in Macao,
Centro Hospitalar Conde de São Januário is responsible
for all of the peritoneal dialysis (PD) patients. Benefitting
from the superior end-stage renal disease (ESRD) fund-
ing system provided by Macao SAR, almost all the* Correspondence: kuokuni@ssm.gov.mo
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reproduction in any medium, provided the orresident patients on chronic dialysis can get free treat-
ment including dialysis and medication. Different from
Hong Kong, there is no PD-first policy in Macao. Never-
theless, PD has been rapidly developed during the past
decade in Macao with about 40% of the PD penetration
rate in chronic dialysis patients [1].
Cardiovascular disease (CVD) is the leading cause of
mortality and morbidity among patients with ESRD on
chronic dialysis [2]. According to U.S. Renal Data System
and Hong Kong Renal Registry reports, CVD accounts
for approximately 40% mortality in dialysis patients and
also is the main cause of hospitalization [3,4]. In keeping
with these facts, data from the Macao Renal RegistryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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utable to CVD. Currently, many available studies have
shown that increased arterial stiffness, which can be
examined by pulse wave velocity (PWV), is a powerful
and independent predictor of all-cause and cardiovascular
mortality in ESRD patients [5,6]. Available study [7]
has clearly shown that the eGFR slope was negatively
associated with baPWV in patients with chronic kidney
disease stages 3 to 5. Moreover, higher baPWV was inde-
pendently associated with progression to commencement
of dialysis or death.
Generally, carotid-femoral PWV (cfPWV), calculated
on the basis of pulse transit time and the distance
travelled by a pulse between carotid artery and femoral
artery, is considered as a well-established index of central
arterial stiffness [8]. However, there are some obvious
limitations for routine use cfPWV measurement in
clinics [9]. Firstly, it is somewhat difficult for clinical
operator to use pressure transducers on target arteries.
Additionally, some subjects may feel uncomfortable
and generally hesitate to exposing inguinal area during
the acquisition of femoral pressure waveforms. Recently,
the brachial–ankle PWV (baPWV) technique has been
developed due to its simple way of measurement by only
wrapping the four extremities with blood pressure cuffs.
Since most CVD events in PD patients are related with
peripheral arteries but not aortic artery, it is important
that baPWV reflects both central and peripheral arterial
stiffness [10]. However, available reports on arterial stiff-
ness in PD patients were limited and cfPWV was used
for assessment in all studies [11-14]. The clinical value
of baPWV in chronic PD patients has not yet been fully
evaluated.
Although an increasing PWV of PD patients is
reported to be significantly associated with age, malnu-
trition, pulse pressure, and peritoneal transport status by
a single-center study in North China [11,12], it has not
yet been elucidated whether there are some dissimilar
impact factors on arterial stiffness among Macao PD
patients who live in South China with inherent variations
in different geographic characteristics, primary diseases,
and underlying medical funding systems. Therefore, this
present study aims to investigate the relationship be-
tween baPWV and its associated risk factors among
chronic PD patients in Macao.
Methods
Patients
We studied all chronic PD patients (n=107) in our
center in this cross-sectional study. All patients were
undergoing continuous PD therapy. Exclusion criteria
were:(1) treatment time <3 months prior to enrollment;
(2) age younger than 18 years; (3) presence of clinically
overt congestive heart failure (NYHA class III-IV);(4) peritonitis less than 1 month before the study; (5) per-
sistent hypotension despite pharmacological therapy
which was defined as systolic blood pressure (BP)
<90 mmHg or diastolic BP <60 mmHg; (6) unwillingness
to participate in our study. Finally, total 96 patients
were included in the study. On enrollment, demographic
and clinical data were collected, including age, gender,
height, weight, body mass index (BMI), BP, presence of
diabetes mellitus, medication history and etiology of
ESRD. The causes of ESRD were as follows: chronic glom-
erulonephritis (n=38), diabetes mellitus (n=34), essential
hypertension or ischemic nephropathy (n=21), obstructive
nephropathy (n=1), lupus nephritis (n=1), polycystic
kidney disease (n=1). Of total 96 patients, 32 patients were
ongoing automatic PD (APD) therapy and 35 patients
were using low glucose degradation product peritoneal
dialysis fluid (Low-GDP PDF). Charlson comorbidity
index (CCI) was scored as described by Beddhu S et al.
[15]. Hyperlipidemia was defined as diagnosed according
to Adult Treatment Panel III criteria or use of statins.
This study was approved by the Ethical Committee of
Centro Hospitalar Conde de São Januário and written
informed consent was obtained from all participants.
Biochemical analysis
Fasting blood samples were collected in the morning.
Measurements were performed using routine laboratory
methods for such serum parameters as creatinine,
calcium, phosphate, albumin, pre-albumin, total choles-
terol, triglyceride, low- and high-density lipoprotein,
ferritin, hematocrit and hemoglobin. Serum C-reactive
protein (CRP) was measured by a high-sensitivity com-
mercial assay. Serum intact parathyroid hormone (iPTH)
was measured by Nichols immunoradiometric assay.
Blood, urine and dialysate samples were collected in
order to calculate weekly Kt/V and creatinine clearance
(CCr).
PWV measurement
The baPWV was assessed using VP-1000 vascular pro-
filer (Nippon Colin Ltd., Komaki City, Japan), which
allowed on-line pulse wave recording and automatic cal-
culation of PWV. Briefly, baPWV was calculated from
the equation: (D1 - D2)/T. D1 is the distance between
the heart and ankle, D2 is the distance between the heart
nd brachium, and T is the transit between the right
brachial arterial wave and right tibial arterial wave. The
distances between the sampling points are automatically
calculated from the patient’s height and are divided by
the time interval for the waveform from each measuring
point. The baPWV was performed in PD patients with
empty abdomen after drainage of dialysate and at least
15 minutes supine rest. Two measurements were per-
formed in each arm, and the average value was used for
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due to ease of measurement, reproducibility and validity
in previous studies [16]. All the PWV measurements
were performed by one experienced operator and the
intra-observer coefficient of variation was about
1.58–3.36%. Patients were divided into two groups
according to mean baPWV value: those above the
mean baPWV value were in the high baPWV group,
while those below the mean baPWV value were in
the low baPWV group.
Statistical analysis
Continuous variables with normal distribution were
expressed as means ± standard deviation, while those
without normal distribution were shown as median and
interquartile range. Comparisons between the two groups
were done by student’s t test or χ2 test. Non-parametric
data were compared with using Mann–Whitney U test.
Univariate analysis was done to explore relationships
between baPWV and other variables by Pearson correl-
ation test for normally distributed data and Spearman
Rank correlation test for non-parametric data (Model 1).
Age-adjusted partial correlation test (Model 2) also was
performed. Step-wise multiple linear regression analysis
was used to assess the independent determinants of
increased baPWV. We included all significant variablesTable 1 Demographic and clinical characteristics of study pop
Variables Total Low ba
(n=96) (
Female Gender 50.0% 37.5%
Age (years) 63.92 ± 14.24 58.34 ±
CCI (score) 5.0 (2.0, 9.0) 4.0 (2.0,
PD duration (Months) 44.47 ± 27.89 40.86 ±
SBP (mmHg) 135.75 ± 20.13 137.07
DBP (mmHg) 76.21 ± 14.58 78.39 ±
MAP (mmHg) 96.06 ± 14.81 97.95 ±
PP (mmHg) 59.54 ± 16.07 58.68 ±
BMI (kg/m2) 23.44 ± 3.65 23.26 ±
Dose of EPO (U/kg.week) 136.95 ± 98.18 137.35
RAS inhibitor use 62.5% 67.9%
β-Blocker use 13.5% 14.3%
Hyperlipidemia 40.6% 39.3%
Previous CVD history 26.0% 16.1%
APD use 33.3% 41.1%
Low-GDP PDF use 36.5% 33.9%
Diabetes mellitus 34.4% 32.1%
baPWV (m/s) 21.20 ± 5.63 17.49 ±
Data were divided into two groups according to mean baPWV value.
Abbreviations: baPWV, brachial-ankle pulse wave velocity; CCI, Charlson comorbidity
pressure; MAP, mean arterial pressure; PP, pulse pressure; BMI, body mass index; EPO
dialysis; GDP, glucose degradation product; PDF, peritoneal dialysis fluid.with respect to the univariate analysis. Variables recog-
nized to present clinical relevance in the current litera-
ture but not presenting statistical significance in our
study were also included. A two tailed P < 0.05 was
considered as statistically significant. All statistical ana-
lyses were performed using the SPSS statistical software
17.0 for Windows (SPSS, Chicago Davis, IL. USA).
Results
Patient characteristics and comparisons between two
subgroups
Table 1 shows the demographic and clinical charac-
teristics of enrolled PD patients and the comparisons
between two subgroup patients divided according to the
mean baPWV value. Compared with low baPWV group
patients, high baPWV group patients were significantly
older (p<0.001) and more likely to have a high proportion
of female gender (p=0.004) as well as previous CVD his-
tory (p=0.008). Table 2 shows the laboratory parameters
of enrolled PD patients and the comparisons between
two subgroup patients. Serum albumin level (p<0.001),
pre-albumin level (p=0.004) and residual renal CCr
(p=0.008) were significantly lower but the serum ferritin
level (p=0.009) was significantly higher in high baPWV
group patients compared with low baPWV group
patients. However, there were no significant differencesulation and comparisons between subgroups
PWV Group High baPWV Group p Value
n=56) (n=40)
67.5% 0.004
14.13 71.73 ± 10.26 <0.001
8.0) 5.0 (3.0, 9.0) 0.054
26.12 49.53 ± 29.80 0.134
± 20.58 133.90 ± 19.59 0.450
13.32 73.15 ± 15.84 0.082
13.95 93.40 ± 15.73 0.138
17.08 60.75 ± 14.68 0.536
3.47 23.70 ± 3.92 0.559








2.41 26.39 ± 4.66 <0.001
index; PD, peritoneal dislysis; SBP, systolic blood pressure; DBP, diastolic blood
, erythropoietin; RAS, renin-angiotensin system; APD, automatic peritoneal
Table 2 Laboratory parameters of study population and comparisons between subgroups
Variables Total Low baPWV Group High baPWV Group p Value
(n=96) (n=56) (n=40)
Serum Albumin(g/L) 38.72 ± 4.85 40.41 ± 3.50 36.35 ± 5.48 <0.001
Pre-Albumin(g/L) 40.16 ± 10.84 42.75 ± 9.61 35.92 ± 11.53 0.004
Cholesterol(mmol/L) 4.82 ± 1.17 4.87 ± 1.35 4.77 ± 0.88 0.682
Triglycerides(mmol/L) 1.92 (0.43, 8.70) 1.79 (0.43, 5.38) 2.08 (0.89, 8.70) 0.314
LDL-cholesterol(mmol/L) 2.72 ± 1.13 2.73 ± 1.23 2.70 ± 0.97 0.909
HDL-cholesterol(mmol/L) 1.22 ± 0.44 1.25 ± 0.50 1.18 ± 0.35 0.451
Hemoglobin(g/dL) 11.17 ± 1.39 11.32 ± 1.41 10.96 ± 1.35 0.214
Hematocrit(%) 32.76 ± 4.26 33.19 ± 4.47 32.15 ± 3.91 0.239
Ferritin(ug/L) 658.89 ± 457.06 549.51 ± 343.48 812.04 ± 548.87 0.009
C-reactive protein(mg/L) 0.41 (0.10, 15.70) 0.37 (0.10, 4.46) 0.59 (0.10, 15.70) 0.104
Calcium(mmol/L) 2.40 ± 0.25 2.37 ± 0.21 2.44 ± 0.30 0.186
Phosphate(mmol/L) 1.53 ± 0.43 1.60 ± 0.44 1.44 ± 0.40 0.071
Calcium-phosphate product[(mmol/L)2] 3.67 ± 1.12 3.79 ± 1.18 3.49 ± 1.02 0.198
intact-PTH(pg/ml) 342.50 (11.50, 1761.00) 360.75 (11.50, 1486.00) 306.20 (56.45, 1761.00) 0.970
Kt/V (total) 2.11 ± 0.58 2.13 ± 0.68 2.09 ± 0.40 0.783
Kt/V (renal) 0.35 ± 0.48 0.43 ± 0.52 0.24 ± 0.41 0.052
CCr (total) 59.04 (42.23, 138.22) 60.58 (42.23, 138.22) 58.37 (42.51, 117.01) 0.476
CCr (renal) 6.16 (0.00, 90.00) 14.52 (0.00, 90.00) 0.46 (0.00, 75.49) 0.008
Data were divided into two groups according to mean baPWV value.
Abbreviations: baPWV, brachial-ankle pulse wave velocity; LDL, low-density lipoprotein; HDL, high-density lipoprotein; PTH, parathyroid hormone; CCr, creatinine
clearance.
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dosage, rennin-angiotensin system inhibitor or β-blocker
use, APD use, low-GDP PDF use, diabetic status,
CRP, serum phosphate and iPTH levels between two
subgroups (all p>0.05).
Correlations between baPWV and related parameters
Table 3 shows the correlations between baPWV and
related parameters by means of univariate analysis. In
brief, Model 1 showed that baPWV was positively asso-
ciated with patients’ age (r=0.534, p<0.001), CCI
(r=0.350, p<0.001) and serum ferritin level (r=0.340,
p=0.001). Meanwhile, baPWV negatively correlated with
serum albumin (r=−0.479, p<0.001), pre-albumin levels
(r=−0.320, p=0.003) and residual renal CCr (r=−0.177,
p=0.048). However, no significant correlation was found
between baPWV and CRP (r=0.182, p=0.076). Results of
partial correlation test from Model 2 by controlling for
age showed that the correlation between CCI and
baPWV was missing, but a significant correlation was
found between baPWV and CRP (r=0.462, p<0.001).
Multivariate regression analysis of determinants of baPWV
In a stepwise multiple linear regression analysis, we
employed baPWV value as a dependent variable, while
using age, CCI, MAP, calcium-phosphate product, serumalbumin level, ferritin level, total cholesterol level, CRP
and residual renal CCr as independent variables.
Table 4 shows the multivariate linear regression ana-
lysis results. Age, serum albumin level, CRP and residual
renal CCr were independently associated with baPWV
(p<0.001, =0.015, =0.019 and =0.045, respectively) and
together explained 51.1% of the total variance.Discussion
Chronic PD patients are at a high risk of developing
accelerated atherosclerosis, vascular stiffness and CVD
incidence secondary to a multitude of traditional and
uremia-specific risk factors [17]. The present study
investigated the arterial stiffness and its associated fac-
tors among stable PD patients in Macao. We found that
baPWV was independently correlated with patient’s age,
serum albumin level and residual renal CCr.
Arterial stiffness has taken on great importance in the
pathophysiology of CVD. In previous studies of general
population as well as ESRD patients, increased arterial
stiffness assessed by PWV was well established as an in-
dependent predictor of all-cause and cardiovascular
mortality [5,18]. More recently, study by Sipahioglu
et al. [19] reported that arterial stiffness was an inde-
pendent risk predictor of mortality and adverse CVD
Table 3 Correlation between pulse wave velocity and related parameters
Variables Model 1 Model 2
Coefficient P Value Coefficient P Value
Age (years) 0.534 <0.001 - -
CCI (score) 0.350 <0.001 0.059 0.592
PD duration (Months) 0.063 0.539 0.128 0.239
SBP (mmHg) −0.003 0.976 0.089 0.418
DBP (mmHg) −0.125 0.226 0.045 0.682
MAP (mmHg) −0.083 0.420 0.070 0.522
PP (mmHg) 0.109 0.290 0.073 0.504
BMI (kg/m2) 0.104 0.314 0.009 0.937
Serum Albumin(g/L) −0.479 <0.001 −0.451 <0.001
Pre-Albumin(g/L) −0.320 0.003 −0.161 0.139
Cholesterol(mmol/L) −0.064 0.538 −0.090 0.408
Triglycerides(mmol/L) 0.022 0.829 −0.018 0.870
LDL-cholesterol(mmol/L) 0.047 0.647 0.064 0.560
HDL-cholesterol(mmol/L) 0.003 0.974 −0.041 0.711
Hemoglobin(g/dL) −0.106 0.306 −0.166 0.126
Hematocrit(%) −0.078 0.451 −0.129 0.235
Ferritin(ug/L) 0.340 0.001 0.293 0.006
C-reactive protein(mg/L) 0.182 0.076 0.462 <0.001
Calcium(mmol/L) 0.071 0.494 −0.002 0.984
Phosphate(mmol/L) −0.147 0.154 0.010 0.924
Calcium-phosphate product[(mmol/L)2] −0.121 0.241 0.004 0.974
intact-PTH(pg/ml) −0.135 0.189 −0.012 0.911
Kt/V (total) −0.025 0.807 −0.093 0.394
Kt/V (renal) 0.110 0.288 −0.294 0.005
CCr (total) −0.013 0.901 −0.276 0.010
CCr (renal) −0.177 0.048 −0.301 0.005
Abbreviations: CCI, Charlson comorbidity index; PD, peritoneal dialysis; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; PP,
pulse pressure; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; PTH, parathyroid hormone; CCr, creatinine clearance.
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show that mortality rate in PD patients continues to
decline, long-term survival remains poor. CVD accounts
for most deaths, therefore, strategies aimed at reducing
modifiable risk factors of CVD have been highlighted
for enhancing long-term survival in PD patients [20].
Given the multivariate regression analysis findings in this




Serum albumin −27.891 11.233
CRP 53.088 22.299
CCr (renal) −3.806 1.874
Abbreviations: CRP, C reactive protein; CCr, creatinine clearance.associated factors with baPWV, cannot be modified.
However, attention needs to be placed on other modifi-
able risk factors which are strongly correlated with in-
creasing arterial stiffness in PD patients, including
improvement of malnutrition status and prevention of
residual renal function.
Hypoalbuminemia is an independent predictor of
increased CVD and mortality in dialysis patients,ed with pulse wave velocity
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sistent with the previous study reported by Gu et al. [12],
we showed that serum albumin level was independently
associated with baPWV in PD patients. Several factors
may contribute to malnutrition in PD patients such as
low protein or energy intakes, psychosocial factors,
catabolic effects of acidosis, dialytic losses of protein or
amino acids, bio-incompatibility of PDF, and infection
[21]. Low serum albumin level may induce micro or
clinical systemic inflammation which may play an addi-
tive role on atherosclerotic vascular disease progression
[22]. Moreover, growing evidences have suggested that
hypoalbuminemia was associated with increased oxida-
tive stress which could accelerate atherosclerosis process
in dialysis patients [23]. In addition, a number of studies
showed that nutritional deficiencies may also play an im-
portant role on endothelial dysfunction in ESRD as well
as dialysis patients [24].
Generally, various factors associated with PD procedure,
such as peritonitis, exit site infection, use of bio-
incompatible PDF may promote inflammation. Protein-
energy malnutrition with micro-inflammation presenting
in a large proportion of chronic PD patients is widely
accepted to be a strong risk factor for cardiovascular
mortality in this patient group [25]. Meanwhile, inflam-
mation has been proposed to be a critical promoter of
atherosclerosis, interacting with many pathophysiologic
pathways to lead to vascular stiffness. Although the
precise link between inflammation and CVD mortality
in PD patients remains unknown, endothelial dysfunc-
tion has been proposed to play an important role in
inflammation-mediated artherosclerosis [26]. CRP, which
is one of the prototypic markers of inflammation, has
been showed to be an important predictor of mortality
and CVD death in PD patients [27]. Inconsistent with
previous single-centre studies in North China [11,12],
we found that CRP was an independent risk factor
for baPWV. Besides the different measurement for
arterial stiffness (baPWV vs cfPWV), it may also partly
be explained by the higher proportion of DM (35.4%
vs 30.0%) and the longer average duration of PD
(44.5 months vs 9.5 months) in our studied population.
It has been clearly established that residual renal func-
tion is related to all-cause mortality and risk of cardio-
vascular death in PD patients [28]. The reanalysis of the
CANUSA study [29] demonstrated that patient survival
was linked with the magnitude of residual renal function.
Each 5-L per week per 1.73 m2 increase in residual
glomerular filtration rate corresponded to a 12% decrease
in the relative risk of death. Neither peritoneal CCr nor
net peritoneal ultrafiltration was associated with patient
survival. In the present study, residual renal CCr, instead
of peritoneal CCr, was independently associated with
baPWV in PD patients. In addition to better soluteclearance and volume removal, residual renal function
was also associated with decreased levels of circulat-
ing inflammatory markers and free radicals, reduced
BP, increased phosphorus removal, and reduced left
ventricular hypertrophy [30]. Taken together, these mul-
tiple factors may contribute to improvement on vascular
endothelial dysfunction and atherosclerosis.
Several limitations of this study must be taken into
consideration when interpreting the data. Firstly, its
cross-sectional design of the study did not allow us to
determine causality. Secondly, although many potential
confounding factors have been assessed, the existence of
other unrecognized variables should be noted. Finally,
due to the technical limitation of baPWV measurement,
patients with atrial fibrillation or amputated extremity
were excluded. However, these PD patients generally are
relevant to high risk of arterial stiffness.
Conclusions
In conclusion, the presented data clearly showed that
arterial stiffness, which was assessed by baPWV, had an
independent correlation with age, serum albumin level,
CRP level and residual renal CCr in PD patients. Further
scaled and prospective studies are warranted to inves-
tigate whether amelioration of malnutrition and micro-
inflammatory status and preserving residual renal function
might prevent the progression of arterial stiffness and re-
duce the CVD incidence among chronic PD patients.
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